AMAG Pharmaceuticals, Inc. (AMAG) financial statements (2021 and earlier)

Company profile

Business Address 1100 WINTER STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments172192261267394428351
Cash and cash equivalents113120150138253287212
Short-term investments5972111129141140139
Receivables947883838585103
Inventory, net of allowances, customer advances and progress billings32292530272831
Inventory32292530272831
Disposal group, including discontinued operation      77
Other undisclosed current assets19432541191312
Total current assets:317341394420525554575
Noncurrent Assets
Operating lease, right-of-use asset2377 
Property, plant and equipment4889877
Intangible assets, net (including goodwill)446610614636640653684
Goodwill423423423423423423423
Intangible assets, net (excluding goodwill)24188192213217231262
Restricted cash and investments0000000
Disposal group, including discontinued operation, noncurrent assets      559
Deferred income tax assets111 
Other noncurrent assets  00100
Other undisclosed noncurrent assets   8111
Total noncurrent assets:4756266306536506621,253
TOTAL ASSETS:7919671,0241,0731,1751,2161,827
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities204199241177144172205
Accounts payable27272722143011
Accrued liabilities177172214156130142194
Deferred revenue 11 
Debt444 212121
Disposal group, including discontinued operation      53
Business combination, contingent consideration, liability0000000
Contract with customer, liability2  0
Other undisclosed current liabilities   4   
Total current liabilities:208204246183165193279
Noncurrent Liabilities
Long-term debt and lease obligation297276273266262258722
Long-term debt, excluding current maturities277273269266262258722
Operating lease, liability2034 
Liabilities, other than long-term debt056512100
Deferred revenue 55 
Contract with customer, liability4   
Disposal group, including discontinued operation, liabilities      98
Other liabilities0001111
Business combination, contingent consideration, liability 000011
Other undisclosed noncurrent liabilities   4   
Total noncurrent liabilities:297282278275263260822
Total liabilities:5054865254584294541,101
Stockholders' equity
Stockholders' equity attributable to parent286481500615747762727
Common stock0000000
Additional paid in capital1,2981,2921,2881,2821,2931,2861,282
Accumulated other comprehensive loss(3)(3)(3)(3)(4)(4)(4)
Accumulated deficit(1,009)(809)(785)(665)(542)(520)(551)
Total stockholders' equity:286481500615747762727
TOTAL LIABILITIES AND EQUITY:7919671,0241,0731,1751,2161,827

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues9084787688122146
Cost of revenue(43)(21)(24)(18)(174)(136)(77)
Cost of goods and services sold(43)(21)(24)(18)   
Gross profit:46635457(86)(14)69
Operating expenses(240)(81)(170)(175)67(6)(28)
Operating income (loss):(194)(18)(116)(118)(19)(19)42
Nonoperating expense(6)(5)(5)(5)(4)(48)(15)
Investment income, nonoperating1112221
Interest and debt expense(7)(6)(6)(6) (36)(16)
Income (loss) from continuing operations before equity method investments, income taxes:(206)(30)(127)(129)(23)(103)11
Other undisclosed income from continuing operations before income taxes7666 3616
Income (loss) from continuing operations before income taxes:(200)(23)(121)(122)(23)(67)27
Income tax expense (benefit)0(0)0032(53)
Loss from continuing operations:(200)(24)(121)(122)(21)(65)(26)
Income from discontinued operations    166
Net loss:(200)(24)(121)(122)(20)(59)(20)
Other undisclosed net income (loss) attributable to parent    (3)90 
Net income (loss) available to common stockholders, diluted:(200)(24)(121)(122)(22)31(20)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(200)(24)(121)(122)(20)(59)(20)
Comprehensive loss:(200)(24)(121)(122)(20)(59)(20)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)01(2)900
Comprehensive income (loss), net of tax, attributable to parent:(200)(24)(120)(121)(22)31(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: